Theodore W. Laetsch, MD
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)
Skip to content
Dr. Theodore Laetsch is a pediatric oncologist and leads both the Developmental Therapeutics Program (DVL) and the Very Rare Malignant Tumors Program (VRMTP) at the Children’s Hospital of Philadelphia, as well as holding national leadership roles in each of these areas within the Children’s Oncology Group (COG).
In the DVL program, Dr. Laetsch conducts early phase clinical trials of new treatments for children with difficult to treat cancers, with a particular area of focus including molecularly targeted therapies that are designed to block specific genetic mutations identified in patients' tumors. In particular, Dr. Laetsch leads the pediatric development of TRK inhibitors for children with NTRK gene fusions, and now leads a COG nationwide clinical trial studying the ability to use TRK inhibitors instead of chemotherapy for children with one of these gene fusions.
While individually very uncommon, together very rare malignant tumors comprise over 10% of childhood cancers. Given the rarity of each individual diagnosis, these cancers have been poorly studied and for many patients there are not standard, defined treatments. As the chair of the Rare Tumors Committee for the Children’s Oncology Group, Dr. Laetsch is working to advance the study of these tumors and define new ways to treat patients. Dr. Laetsch is hopeful that we can advance the care of patients with these tumors by using cancer genomics to identify targetable mutations as well as studying immunotherapy, which has revolutionized the care of many of these cancers in adult patients.
Finally, Dr. Laetsch is a member of the cellular therapy / chimeric antigen receptor (CAR) T-cell team at the Children’s Hospital. Prior to joining the Children’s Hospital in 2020, Dr. Laetsch led the pediatric CAR T-cell program at the University of Texas Southwestern Medical Center.
In each of these areas, Dr. Laetsch provides clinical care and conduct research, with an overarching goal of improving treatment options for children with difficult to treat cancers.
MD - University of California, San Francisco, San Francisco, CA
Pediatrics, University of Colorado School of Medicine, Denver Children's Hospital, Aurora, CO
Pediatrics - University of Colorado School of Medicine, Denver Children's Hospital, Aurora, CO
Pediatric Hematology-Oncology - Children's Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology-Oncology – American Board of PediatricsPediatrics – American Board of Pediatrics
"Reimagining Pediatric Oncology Drug Development in the Era of Targeted Therapy." Cook's Children's Hospital, Ft. Worth, TX
"Chimeric Antigen Receptor T-cells for Pediatric Cancer." Leukemia and Lymphoma Society Luncheon, UT Southwestern Medical Center, Dallas, TX
"Experimental Therapeutics Program for Childhood Cancer." Children's Medical Center Foundation, Dallas, TX
"Chimeric Antigen Receptor T-cells." Scott Storm Nursing Conference, Dallas, TX
"TRK Inhibitors: New treatment, Potential New Toxicities - What We Would Like to Know." FDA Mini-symposium, Washington, DC
"Targeting Pediatric Cancer." Dell Children's Hospital, Austin, TX
"Targeting Pediatric Cancer." Texas Tech University, Lubbock, TX
"Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors." DHART SPORE Retreat, Indiana University, Indianapolis, IN
"MassARRAY Sequencing of Pediatric NRSTS Tumors." MassARRAY Sequencing of Pediatric NRSTS Tumors
"Philips CRB Today: MR-HIFU hyperthermia in oncological applications", Philips Webinar, Finland and USA
"MassARRAY Sequencing of Pediatric NRSTS Tumors.", Baylor College of Medicine, Houston, TX
"Grand Rounds: Novel Cellular Therapies for Pediatric Leukemia." Texas Tech University Health Sciences Center, Lubbock, TX
Novel Cellular Therapies for Pediatric Leukemia, University of Texas Health Sciences Center, San Antonio, TX
"CART19 Therapy for Pediatric ALL." Heme/Onc Grand Rounds, Cook Children's Hospital, Fort Worth, TX
TW Laetsch. DS Hawkins.: Larotrectinib for the treatment of TRK fusion solid tumors. Expert Review of Anticancer Therapy 19(1): 1-10, Jan 2019.
CM Albert*, JL Davis*, N Federman, M Casanova, TW Laetsch.: TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. Journal of Clinical Oncology 37(6): 513 - 524, Feb 2019.
AJ Kansagra*, NV Frey*, M Bar*, TW Laetsch*, PA Carpenter, BN Savani, HE Heslop, CM Bollard, KV Komanduri, DA Gastineau, C Chabannon, MA Perales, M Hudecek, M Aljurf, L Andritsos, JA Barrett,V Bachanova, C Bonini, A Ghobadi, SI Gill, J Hill, S Kenderian, P Kebriaei, A Nagler, D Maloney, HD Liu, NN Shah, MA Kharfan-Dabaja, EJ Shpall, GJ Mufti, L Johnston, E Jacoby, A Bazarbachi, JF DiPersio, SZ Pavletic, DL Porter, SA Grupp, M Sadelain, MR Litzow, M Mohty, SK Hashmi. : Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Biology of Blood and Marrow Transplantation 25(3): e76-e85. Mar 2019.
AJ Kansagra*, NV Frey*, M Bar*, TW Laetsch*, PA Carpenter, BN Savani, HE Heslop, CM Bollard, KV Komanduri, DA Gastineau, C Chabannon, MA Perales, M Hudecek, M Aljurf, L Andritsos, JA Barrett,V Bachanova, C Bonini, A Ghobadi, SI Gill, J Hill, S Kenderian, P Kebriaei, A Nagler, D Maloney, HD Liu, NN Shah, MA Kharfan-Dabaja, EJ Shpall, GJ Mufti, L Johnston, E Jacoby, A Bazarbachi, JF DiPersio, SZ Pavletic, DL Porter, SA Grupp, M Sadelain, MR Litzow, M Mohty, SK Hashmi. : Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant 54(11): 1868-1880, Nov 2019 Notes: Clinical practice guidelines.
HL Pacenta, TW Laetsch, S John. : CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia. Paediatric Drugs Nov 2019.
Laetsch TW, Maude SL, Milone MC, Davis KL, Krueger J, Cardenas AM, Eldjerou LK, Keir CH, Wood PA, Grupp SA. : False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. Blood 131(23): 2596-2598, Jun 2018 Notes: doi:10.1182/blood-2017-12-822940.
Wu LW, Pavlock T, Patterson A, Post A, Ambrose C, Rajaram V, Pavlick DC, Cooke M, Miller VA, Albacker LA, Ali SM, Smith S, Cox MC, Martin A, Megison S, Laetsch TW.: Durable Clinical Response to Larotrectinib in an Adolescent Patient with an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion. JCO Precision Oncology Aug 2018 Notes: doi: 10.1200/PO.18.00101
TW Laetsch, R Nagasubramanian, M Casanova.: Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma. Pediatric Blood and Cancer Apr 2017 Notes: doi:10.1002/pbc.26593.
TW Laetsch, R Nagasubramanian, M Casanova. : Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma. Pediatric Blood and Cancer Apr 2017 Notes: Letter to the Editor. doi:10.1002/pbc.26593.
C Allen, TW Laetsch, R Mody, MS Irwin, M Lim, PC Adamson, NL Seibel, DW Parsons, YJ Cho, K Janeway. : Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial. Journal of the National Cancer Institute 109(5), May 2017 Notes: doi:10.1093/jnci/djw274.
NL Seibel, K Janeway, CE Allen, SN Chi, YJ Cho, J Glade Bender, A Kim, TW Laetsch, MS Irwin, N Takebe, JV Tricoli, DW Parsons. : Pediatric Oncology Enters the Era of Precision Medicine. Current Problems in Cancer 41(3): 194 - 200, May-Jun 2017 Notes: doi:10.1016/j.currproblcancer.2017.01.002.
V Huynh, TW Laetsch, R Schore, P Gaynon, MM O'Brien. : Redefining Treatment Failure for Pediatric Acute Leukemia in the Era of Minimal Residual Disease Testing. Pediatric Hematology Oncology Page: 1-14, Nov 2017.
M Rosenzweig, S Ali, MD, V Wong, AB. Schrock, TW Laetsch, A Heilmann, S Morley, Y Chudnovsky, RL. Erlich, K Wang, PJ Stephens, JS Ross, VA Miller, J Oesterheld.: A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion. Pediatric Blood Cancer Dec 2016 Notes: doi: 10.1002/pbc.26377.
E Williams, TJ Brown, P Griffith, AS Rahimi, R Oilepo, H Hammers, TW Laetsch, P Currykosky, S Partridge, MS Beg. : Improving the Time-to-Activation of new Clinical Trials at an NCI-Designated Comprehensive Cancer Center. Journal of Oncology Practice Jan 2020.
A Shuen, S Lanni, G Panigrahi, M Edwards, L Yu, B Campbell, A Mandel, C Zhang, N Zhukova, M Alharbi, M Bernstein, S Berry, A Broniscer, D Bowers, S Carroll, K Cole, S Constantini, B Crooks, R Dvir, R Farah, N Hijiya, B George, TW Laetsch, V Larouche, S Lindhorst, R C Luiten, V Magimairajan, G Mason, W Mason, O Mordechai, N Mushtaq, G Nicholas, M Oren, L Palma, L Alberto Pedroza, J Ramdas, D Samuel, K W Schneider, A Seeley, K Semotiuk, A Shamvil, D Sumerauer, H Toldeano, P Tomboc, M Wierman, A Van Damme, Y Lee, M Zapotocky, A Zorzi, E Bouffet, C Durno, M Aronson, S Gallinger, W D Foulkes, D Malkin, U Tabori, C Pearson. : Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue. Journal of Clinical Oncology 37(6): 461 - 470, Feb 2019.
JL Davis, CM Lockwood, B Stohr, C Boecking, A Al-Ibraheemi, SG DuBois, SO Vargas, JO Black, MC Cox, M Luquette, B Turpin, S Szabo, TW Laetsch, CM Albert, DM Parham, DS Hawkins, ER Rudzinski. : Expanding the Spectrum of Pediatric NTRK-rearranged mesenchymal tumors. American Journal of Surgical Pathology 43(4): 435 - 445, Apr 2019.
A Stein, S Grupp, J Levine, TW Laetsch, M Pulsipher, M Boyer, K August, B Levine, L Tomassian, S Shah, M Leung, PH Huang, R Awasthi, K Mueller, P Wood, and C June.: Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR)-T Cells. CPT: Pharmacometrics & Systems Pharmacology 8(5): 285 - 295, May 2019.
M Hassan, E Butler, R Wilson, A Roy, Y Zheng, P Liem, D Rakheja, D Pavlick, LL Young, M Rosenzweig, R Erlich, SM Ali, PJ Leavey, DW Parsons, SX Skapek, TW Laetsch.: Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib. Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5) Cold Spring Harbor Molecular Case Studies 5(5), Oct 2019.
TW Laetsch, GD Myers, A Baruchel, AC Dietz, MA Pulsipher, H Bittencourt, J Buechner, B De Moerloose, KL Davis, E Nemecek, T Driscoll, F Mechinaud, N Boissel, S Rives, P Bader, C Peters, HS Sabnis, SA Grupp, GA Yanik, H Hiramatsu, HE Stefanski, L Rasouliyan, L Yi, S Shah, J Zhang, AC Harris.: Patient-Reported Quality of Life Following Tisagenlecleucel Infusion in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in a Multicenter Single-Arm Phase 2 Trial. Lancet Oncology Oct 2019.
C Bing, RM Staruch, B Cheng, J Nofiele, D Szczepanski, M Wodzak Staruch, A Farrow- Gillespie, A Yang, TW Laetsch, R Chopra.: Breath-hold MR-HIFU hyperthermia: phantom and in vivo feasibility. International Journal of Hyperthermia 36(1): 1084 - 1097, Nov 2019.
L Xu, Y Zheng, J Liu, D Rakheja, S Singleterry, TW Laetsch, JF Shern, J Khan, TJ Triche, DS Hawkins, JF Amatruda, SX Skapek. : Integrative Bayesian analysis identifies rhabdomyosarcoma disease genes. Cell Reports 24(1): 238 - 251, Jul 2018 Notes: doi: 10.1016/j.celrep.2018.06.006.
Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL. : Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. American Journal of Surgical Pathology 42(7), Jul 2018 Notes: doi: 10.1097/PAS.0000000000001062
Laetsch TW, Roy A, Xu L, Black JO, Coffin CM, Chi YY, Tian J, Spunt SL, Hawkins DS, Bridge JA, Parsons DW, Skapek SX. : Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group. Clinical Cancer Research 24(16): 3888 - 3897, Aug 2018 Notes: doi: 10.1158/1078-0432.CCR-18-067
SG DuBois, TW Laetsch, N Federman, B Turpin, CM Albert, R Nagasubramanian, ME Anderson, JL Davis, H Qamoos, M Reynolds, S Cruickshank, MC Cox, DS Hawkins, L Mascarenhas, AS Pappo. : The Use of Neoadjuvant Larotrectinib in the Management of Children with Locally Advanced TRK Fusion Sarcomas. Cancer 124(21): 4241-4247, Nov 2018.
C Bing, P Patel, RM Staruch, S Shaikh, J Nofiele, MW Staruch, D Szczepanski, NS Williams, TW Laetsch, and R Chopra.: Longer heating duration increases localized doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin. International Journal of Hyperthermia 36(1): 196-203, Dec 2018.
Mueller KT, Waldron ER, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August K, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah S, Leung M, Taran T, Wood PA, Maude SL. : Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research 24(24): 6175 - 6184, Dec 2018.
A Drilon*, TW Laetsch*, S Kummar, SG DuBois, UN Lassen, GD Demetri, M Nathenson, RC Doebele, AF Farago, AS Pappo, B Turpin, A Dowlati, MS Brose, L Mascarenhas, Federman N, J Berlin, WS El-Deiry, C Baik, J Deeken, V Boni, R Nagasubramanian, M Taylor, ER Rudzinski, F Meric-Bernstam, DPS Sohal, PC Ma, LE Raez, JF Hechtman, R Benayed, M Ladanyi, BB Tuch, K Ebata, S Cruickshank, NC Ku, MC Cox, DS Hawkins, DS Hong, DM Hyman. : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. New England Journal of Medicine 378(8): 731 - 739, Feb 2018.
Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA. : Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia Mar 2018 Notes: doi: 10.1038/s41375-018-0094-0.
KS Chen, NJ. Fustino, AA Shukla, EK Stroup, A Budhipramono, C Ateek, S Stuart, K Yamaguchi, P Kapur, AL Frazier, L Lum, LHJ Looijenga, TW Laetsch, D Rakheja, and JF Amatruda. : EGF Receptor and mTORC1 are novel therapeutic targets in nonseminomatous germ cell tumors. Molecular Cancer Therapeutics 17(5): 1079 - 1089, May 2018 Notes: doi:10.1158/1535-7163.MCT-17-0137.
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM,Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS. : Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncology 19(5): 705-714, May 2018 Notes: doi: 10.1016/S1470-2045(18)30119-0.
EK Stroup, Y Yeu, A Budhipramono, TH Hwang, D Rakheja, A Erdreich-Epstein, TW Laetsch, JF Amatruda, KS Chen. : WTâ€CLS1 is a rhabdoid tumor cell line and can be inhibited by miRâ€16. Cancer Reports Jul 2018 Notes: e1110. doi:10.1002/cnr2.1110.
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, P Bader, MR Verneris, H Stefanski, GD Myers, M Qayed, B De Moerloose, H Hiramatsu, K Schlis, K Davis, PL Martin, ER Nemecek, G Yanik, C Peters, A Baruchel, N Boissel, F Mechinaud, A Balduzzi, J Krueger, CH June, BL Levine, P Wood, T Taran, KT Mueller, Y Zhang, K Sen, D Lebwohl,MA Pulsipher*, SA Grupp*. : Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine 378(5): 439 - 448, Feb 2017 Notes: doi:10.1056/NEJMoa1709866.
BB Campbell, N Light, D Fabrizio, M Zatzman, F Fuglini, Rde Borja, S Davidson, M Edwards, J Elvin, KP Hodel, WJ Zahurancik, Z Suo, T Lipman, K Wimmer, CP Kratz, DC Bowers, TW Laetsch, GP Dunn, J Tanner, MR Grimmer, I Smirnov, V Larouche, D Samuel, A Bronsema, M Osborn, D Stearns, P Raman, KA Cole, PB Storm, M Oren, E Opocher, G Mason, G Thomas, M Sabel, B George, DS Ziegler, L Scott, VM Issai, S Constantini, H Toledano, R Elhasid, R Farah, R Dvir, P Dirks, A Huang, M Galati, B Chung, V Ramaswamy, MS. Irwin, M Aronson, C Durno, MD Taylor, G Rechavi, JM Maris, E Bouffet, C Hawkins, JF Costello, MS Meyn, ZF Pursell, D Malkin, U Tabori, A Shlien. : Comprehensive Analysis of Hypermutation in Human Cancer. Cell 171(5): 1042-1056, Nov 2017 Notes: e10.doi: 10.1016/j.cell.2017.09.048.
C Bing, R Staruch, M Tillander, MO Köhler, C Mougenot, M Ylihautala, TW Laetsch, Chopra R.: Drift correction for accurate PRF shift MR thermometry during mild hyperthermia treatments with MR-HIFU. International Journal of Hyperthermia 22: 1-15, May 2016.
L Xu, RA Wilson, TW Laetsch, D Oliver, SL Spunt, DS Hawkins, SX Skapek. P.: Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group. Scientific Reports 6: 33429, Sep 2016 Notes: doi:10.1038/srep33429.
NF Evageliou, M Haber, A Vu, TW Laetsch, J Murray, L Gamble, NC Cheng, X Liu, M Reese, KA Corrigan, DS Ziegler, H Webbeer, CS Hayes, B Pawel, GM Marshall, H Zhao, SK Gilmour, MD Norris, MD Hogarty.: Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. Clinical Cancer Research 22(17): 4391-4404, Sep 2016 Notes: doi:10.1158/1078-0432.CCR-15-2539.
J Shim, RM Staruch, K Koral, XJ Xie, R Chopra, TW Laetsch.: Pediatric Sarcomas Are Targetable by MR-Guided High Intensity Focused Ultrasound (MR-HIFU): Anatomical Distribution and Radiological Characteristics. Pediatric Blood and Cancer 63(19): 1753 - 1760, Oct 2016 Notes: doi: 10.1002/pbc.2607.
E Ramsay, C Mougenot, M Kazem, TW Laetsch, R Chopra.: Dual-echo gradient echo imaging for simultaneous temperature mapping in bone. Magnetic Resonance in Medicine 74(4): 1095 - 1102, Oct 2015.
TW Laetsch, X Liu, A Vu, M Sliozberg, M Vido, OU Elci, KC Goldsmith, and MD Hogarty.: Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma. Cell Death and Disease e1072: 5, Feb 2014 Notes: doi: 10.1038/cddis.2014.40.
2009-present Children's Oncology Group (Member)
2015-present Children's Oncology Group/National Cancer Institute, Pediatric MATCH Target Agent and Prioritization (TAP) Committee (Member)
2016-present Children's Oncology Group/National Cancer Institute, Pediatric MATCH Leadership Committee (Member)
2016-present International Society of Paediatric Oncology (SIOP) (Member)
2017-present Connective Tissue Oncology Society (CTOS) (Member)
2005-2008 American Academy of Pediatrics (Member and Program Delegate)
2009-present American Society of Pediatric Hematology/Oncology (ASPHO) (Member)
2010-present American Association for Cancer Research (AACR) (Member)
2010-present American Society of Clinical Oncology (ASCO) (Member)
2015-present Children's Oncology Group/Children's Oncology Group, Target and Agent Prioritization Committee (Member)
2015-2016 Novartis, American Society of Hematology (ASH) Data and Customer Model Advisory Board (Member) br> 2016-present Eli Lilly (Consultant)
2016-2018 Loxo Oncology (Consultant)
2016 National Cancer Institute, Cancer Center Data Sharing Workshop (Member)
2016-present Novartis Pharmaceuticals (Consultant)
2017-present National Institutes of Health, ClinGen Somatic Variant Curation Taskforce (Member)
2017 The Naya Foundation (No More Kids with Cancer Clinical/Translational Research Award Grant Reviewer)
2018-present American Society of Hematology (ASH) (Member)
2018-present Bayer (Consultant)
2018-2019 Focused Ultrasound Foundation (Ad Hoc Grant Reviewer)
2019-present American Society of Clinical Oncology (ASCO), Annual Meeting Education Committee (Track Leader (Pediatric Oncology))
2019-Present Children's Oncology Group, Rare Tumors Committee (Chair)
2019-present National Institutes of Health, ClinGen NTRK fusion Variant Curation Expert Panel (VCEP) (Member)
2019 One Million for Anna Foundation (Ad Hoc Grant Reviewer)
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.